Leading the TAME trial to prove aging can be targeted with metformin
Nir Barzilai is the director of the Institute for Aging Research at Albert Einstein College of Medicine and lead investigator of the landmark TAME (Targeting Aging with Metformin) trial. His research on centenarians has revealed genetic factors that contribute to exceptional longevity. The TAME trial aims to prove that aging itself can be targeted as a condition, potentially revolutionizing how the FDA views aging interventions.